左西孟旦治疗心力衰竭患者的研究进展  

Progress of Lewsimendan in Patients with Heart Failure

作　　者：廖文超[1] LIAO Wenchao(Tianjin Xiqing Hospital,Tianjin 300000,China)

机构地区：[1]天津市西青医院,天津300000

出　　处：《药品评价》2021年第21期1342-1344,共3页Drug Evaluation

摘　　要：心力衰竭(CFR)是多种心血管疾病进展至终末期的表现,亦为大部分器质性心脏病发展到最后的表现,该病致死率常年居高不下,给患者生命安全造成威胁。CFR发病机制较繁杂,多与心肌损伤、心室重构、血流动力学异常等因素有关。目前,传统治疗中的正性肌力药物存有影响心肌扩张、增加心肌耗氧量等不良状况,在临床应用中较为受限。随着钙离子增敏剂——左西孟旦的出现,该药物满足临床急切改善心衰症状、不增加耗氧量、稳定血流动力学异常等相关需求,且已通过多项临床试验证明其安全性与疗效。现就左西孟旦治疗CFR患者的临床应用进行综述。Heart failure (CFR) is a manifestation of progression to end of cardiovascular disease and the end of most organic heart disease with perennial mortality and a risk to life safety.The pathogenesis of CFR is more complicated,which is mostly related to myocardial injury,ventricular remodeling,hemodynamic abnormalities and other factors.At present,the positive muscle force drugs in the traditional treatment have adverse conditions affecting myocardial expansion and increasing myocardial oxygen consumption,which are relatively limited in clinical application.With the emergence of calcium ion sensitizer-lewsimendan,the drug meets the clinical need to improve heart failure symptoms,does not increase oxygen consumption,and has stable hemodynamic abnormalities,and has proved its safety and efficacy through several clinical trials.The clinical application of lewsimendan in the treatment of CFR patients is reviewed.

关 键 词：心力衰竭 左西孟旦 心室重构 血流动力学 

分 类 号：R541.6[医药卫生—心血管疾病]